A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: The TRIMCI study

Teresa Gómez-Isla, Rafael Blesa, Merce Boada, Jordi Clarimón, Teodoro Del Ser, Gemma Domenech, Jose M. Ferro, Beatriz Gómez-Ansón, Jose M. Manubens, Jose M. Martínez-Lage, David Muñoz, Jordi Peña-Casanova, Ferran Torres

Research output: Contribution to journalArticleResearchpeer-review

53 Citations (Scopus)

Abstract

BACKGROUND: Amnestic mild cognitive impairment represents, in many cases, the earliest clinical phases of Alzheimer disease. Anti-inflammatory agents have epidemiologic support as drugs potentially beneficial in Alzheimer disease. In vivo studies have shown that Triflusal and its active metabolite 2-hydroxy-4-trifluoromethyl-benzoic acid have potent anti-inflammatory actions in the central nervous system. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of Triflusal in patients with amnestic mild cognitive impairment. Subjects were randomly assigned to receive 900mg of Triflusal or placebo for 18 months. The primary outcome was a change in Cognitive subscale of the Alzheimer Disease Assessment Scale; conversion to dementia was a secondary outcome. RESULTS: A slow rate of recruitment forced a premature cessation of the study. Two hundred and fifty-seven subjects were enrolled and followed-up for an average of 13 months. The significance level was not reached for the primary outcome even though a trend in favor of Triflusal was observed. However, there was a significant difference in the probability of progression to dementia of Alzheimer's type with a lower risk in the Triflusal compared with the placebo group (hazard ratio, 2.10; 95% confidence interval, 1.10-4.01; P=0.024). CONCLUSIONS: In this study, Triflusal therapy was associated with a significant lower rate of conversion to dementia that is likely to be clinically relevant. Because the trial was prematurely halted, these results should be interpreted with caution and require further confirmation. © 2008 Lippincott Williams & Wilkins, Inc.
Original languageEnglish
Pages (from-to)21-29
JournalAlzheimer Disease and Associated Disorders
Volume22
Issue number1
DOIs
Publication statusPublished - 1 Jan 2008

Keywords

  • Alzheimer disease
  • Amnestic mild cognitive impairment
  • Triflusal

Fingerprint

Dive into the research topics of 'A randomized, double-blind, placebo controlled-trial of triflusal in mild cognitive impairment: The TRIMCI study'. Together they form a unique fingerprint.

Cite this